Xbrane Biopharma AB (XBRANE) AI Stock Analysis

• Market Cap: kr380.29M
• Dividend Yield: N/A
• Average Volume (3M): 12.31M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.26
• Revenue Growth: 45.52%
• EPS Growth: 93.35%
• Country: SE
• Employees: 65
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 1,532,190,300
• 10 Day Avg. Volume: 7,680,898
• 30 Day Avg. Volume: 12,308,463
• PEG Ratio: 7.44
• Price to Book (P/B): 43.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -72.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: kr0.00 ▼(-100.00%Downside)

The overall stock score of 46.75 reflects significant financial challenges and valuation concerns, with a slight offset from technical analysis suggesting mild positive momentum. The primary risks relate to unprofitability and liquidity issues, while the lack of earnings call and corporate events data limit additional insights.

Xbrane Biopharma AB Business Overview & Revenue Model

Company Description

Xbrane Biopharma AB is a biotechnology company specializing in the development and commercialization of biosimilars, which are biologic medical products highly similar to already approved reference products. The company operates primarily in the pharmaceutical sector, focusing on creating cost-effective and accessible alternatives to existing biologic therapies. Xbrane's core products include biosimilars targeting therapeutic areas such as oncology and ophthalmology.

How the Company Makes Money

Xbrane Biopharma AB generates revenue primarily through the development and commercialization of biosimilar products. The company's revenue model involves partnering with larger pharmaceutical firms to advance biosimilar candidates through clinical trials and regulatory approval processes. These partnerships often include licensing agreements, where Xbrane receives upfront payments, milestone payments, and royalties based on the sale of approved biosimilar products. Additionally, Xbrane may earn revenue from contract development services and collaborations with other biopharmaceutical companies, leveraging its expertise in biosimilar development to support third-party projects. Strategic alliances and out-licensing deals are significant contributors to Xbrane's earnings, enabling the company to share the financial risks and benefits associated with bringing biosimilars to market.

Xbrane Biopharma AB Financial Statement Overview

Summary

Xbrane Biopharma AB faces significant financial challenges, characterized by consistent losses and cash flow issues. Despite a strong gross profit margin and moderate debt-to-equity ratio, the company struggles with profitability and cash generation. The focus should be on improving revenue growth and operational efficiency to ensure long-term sustainability.

Income Statement

Xbrane Biopharma AB has demonstrated a volatile revenue growth trajectory, with a recent decline from the previous year. The company exhibits a negative net profit margin and EBIT margin, indicating ongoing struggles with profitability. Despite a strong gross profit margin, the continuous negative net income presents a significant challenge.

Balance Sheet

The company's balance sheet reveals a moderate debt-to-equity ratio, which is a positive indicator of leverage management. However, the declining equity ratio suggests increasing liabilities relative to assets. Return on equity remains negative, reflecting poor profitability levels impacting shareholder value.

Cash Flow

Xbrane Biopharma AB's cash flow statement shows negative free cash flow, with a free cash flow to net income ratio indicating substantial cash outflows exceeding net income. The operating cash flow remains negative, suggesting ongoing liquidity challenges. Financing activities have been a key source of cash, highlighting dependency on external funding.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	198.70M	238.73M	57.62M	11.53M	6.82M
Gross Profit	180.47M	35.39M	41.04M	-684.00K	2.45M
EBITDA	-181.97M	-282.03M	-149.34M	-167.59M	-213.07M
Net Income	-266.22M	-388.17M	-172.23M	-191.01M	-226.79M
Balance Sheet
Total Assets	842.43M	653.51M	690.51M	688.43M	463.76M
Cash, Cash Equivalents and Short-Term Investments	124.33M	65.40M	193.99M	295.18M	243.14M
Total Debt	191.72M	231.48M	38.22M	44.38M	6.26M
Total Liabilities	633.89M	482.17M	265.63M	256.69M	206.06M
Stockholders Equity	208.54M	171.34M	424.89M	431.74M	257.71M
Cash Flow
Free Cash Flow	-185.97M	-423.45M	-254.04M	-296.96M	-242.26M
Operating Cash Flow	-133.73M	-406.68M	-193.92M	-219.61M	-238.41M
Investing Cash Flow	-52.25M	-16.77M	-60.13M	-77.35M	-3.85M
Financing Cash Flow	243.62M	298.70M	148.86M	349.37M	322.72M

Xbrane Biopharma AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XBRANE, the sentiment is Positive. The current price of 0.24 is below the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.23, and above the 200-day MA of 0.19, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.75 is Neutral, neither overbought nor oversold. The STOCH value of 52.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XBRANE.

Xbrane Biopharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMMU	51 Neutral	€440.11M	―	-18.79%	―	―	21.85%
Sector *	50 Neutral	kr5.46B	12.72	-80.61%	5.07%	37.36%	27.71%
XBRANE	47 Neutral	kr380.29M	―	-47.73%	―	45.52%	93.35%
ONCO	46 Neutral	kr362.53M	―		―	1.72%	32.54%
IVACC	42 Neutral	kr331.95M	―	-24.61%	―	47.06%	33.86%
ISOFOL	36 Underperform	€243.89M	―	-54.29%	―	-100.00%	-17.35%
GUARD	32 Underperform	€350.92M	―	-205.65%	―	―	24.25%

Xbrane Biopharma AB Corporate Events

Xbrane Biopharma Approves Directed Share Issue to Bolster Financial Position

Xbrane Biopharma AB held an extra general meeting where it approved a directed issue of shares, deviating from shareholders’ preferential rights. This strategic move is intended to strengthen the company’s financial position, attract reputable long-term shareholders, and support its ongoing development and commercialization of biosimilars. The decision to opt for a directed issue over a rights issue is based on factors such as time efficiency, cost-effectiveness, and minimizing market risk exposure.

Xbrane Biopharma Announces SEK 240 Million Directed Share Issue to Boost Biosimilar Development

Xbrane Biopharma AB has announced a directed share issue, subject to approval by an Extraordinary General Meeting, to raise approximately SEK 240 million. This funding will support the company’s regulatory processes, production costs, and general corporate purposes, positioning Xbrane to capitalize on its biosimilar products, Ximluci® and Xdivane™, and potentially achieve cash-flow positivity. The recent transaction with Alvotech, involving the sale of a biosimilar candidate and organizational restructuring, is expected to significantly reduce Xbrane’s fixed costs and enhance its financial flexibility, enabling a stronger focus on its core biosimilar programs.

Xbrane Biopharma Announces Extra General Meeting for Share Issue

Xbrane Biopharma AB has announced an extra general meeting to discuss a proposed directed issue of shares, which involves issuing up to 1,043,478,260 new shares. This move is aimed at raising capital, with a total potential increase in share capital of SEK 233,933,281.222894. The subscription price is set at SEK 0.23 per share, determined through an accelerated bookbuilding procedure. This strategic decision is expected to strengthen the company’s financial position and support its market expansion efforts, potentially impacting stakeholders by enhancing the company’s capability to compete in the biosimilar market.

Xbrane Biopharma Announces SEK 200 Million Directed Share Issue

Xbrane Biopharma AB announced a directed issue of shares worth approximately SEK 200 million to institutional and qualified investors. This move is aimed at financing regulatory processes, paying suppliers, and supporting general corporate purposes. The company recently completed a transaction with Alvotech, selling its biosimilar candidate and parts of its organization, which is expected to reduce annual fixed costs significantly. The directed issue is seen as a strategic decision to strengthen the company’s financial position, diversify its shareholder base, and support the development and commercialization of its biosimilars.

Xbrane Biopharma Strengthens Focus with Sale of XB003 to Alvotech

Xbrane Biopharma has completed the sale of its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction strengthens Xbrane’s financial position, allowing the company to focus on its remaining programs, particularly Ximluci and Xdivane, and continue its work in biosimilar development to create value for shareholders and patients.

Xbrane Biopharma Advances Biosimilar Candidate Towards FDA Approval

Xbrane Biopharma AB has re-submitted its Biologics License Application to the US FDA for its biosimilar candidate to LUCENTIS® (ranibizumab), aimed at treating conditions such as age-related macular degeneration. The FDA has set a decision date for October 2025, contingent on successful re-inspections of manufacturing sites. This move underscores Xbrane’s commitment to providing cost-effective treatment alternatives and could enhance its position in the biosimilar market.

Xbrane Biopharma Strengthens Financial Position with Strategic Asset Sale

Xbrane Biopharma AB announced a strategic move to sell its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction is expected to strengthen Xbrane’s financial position by reducing annual fixed costs by around SEK 120 million and allowing the company to focus on its core products, Ximluci® and Xdivane™, which are anticipated to generate significant revenue through royalties and profit sharing. The company also reported strong growth for Ximluci® in Europe and is progressing with regulatory processes in the US, while preparing for a clinical trial for Xdivane™.

Xbrane Biopharma AB Announces Key Resolutions from Annual General Meeting

Xbrane Biopharma AB’s annual general meeting resulted in several key resolutions, including the adoption of the income statement and balance sheet, the decision not to distribute dividends, and the re-election of board members and auditors. The meeting also established remuneration for directors and committee members and set guidelines for senior executive remuneration, while withdrawing a proposal for issuing shares due to insufficient support.